Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Gilead Sciences Ireland UC .
Filed returns
27
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2026 | Gilead Sciences Ireland UC | Health | Meetings to discuss health policy, service capacity and access to medicine (Matters involving public funds) | 8 | On lobbying.ie |
| Jan–Apr 2026 | Gilead Sciences Ireland UC | Health | Emails to raise HIV health policy issues (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2026 | Gilead Sciences Ireland UC | Health | Meetings to discuss health policy and access to medicine (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2025 | Gilead Sciences Ireland UC | Health | Meetings to discuss HIV health policy and general access to medicine (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2025 | Gilead Sciences Ireland UC | Health | Meetings to discuss HIV and Hep-C health-policy (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Gilead Sciences Ireland UC | Health | Sent email to DPO's to request meeting to discuss HIV Action Plan (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Gilead Sciences Ireland UC | Health | Sent email to DPO's to consider, in Programme for Government, a plan of action to reach 2030 HIV healthcare policy goals (Public policy or programme) | 7 | On lobbying.ie |
| Sep–Dec 2024 | Gilead Sciences Ireland UC | Health | Sent email to DPO's to consider, in election manifestos, a plan of action to reach 2030 HIV healthcare policy goals (Public policy or programme) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Gilead Sciences Ireland UC | Health | Meeting with MEPs at Gilead Manufacturing site in Carrigtwohill, Cork. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2024 | Gilead Sciences Ireland UC | Health | Meetings with political stakeholders to share local company perspective on opportunities and challenges of operating in Ireland including (Matters involving public funds) | 3 | On lobbying.ie |
| Jan–Apr 2024 | Gilead Sciences Ireland UC | Health | Draw attention to industry anticipated impact of upcoming EU Pharma legislation on the innovative pharmaceutical industry (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2023 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2023 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2022 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 7 | On lobbying.ie |
| May–Aug 2022 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 2 | On lobbying.ie |
| Jan–Apr 2022 | Gilead Sciences Ireland UC | Health | HIV, Hepatitis-C & Oncology healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Gilead Sciences Ireland UC | Health | HIV & hepatitis-C healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 1 | On lobbying.ie |
| May–Aug 2021 | Gilead Sciences Ireland UC | Health | HIV & hepatitis-C healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2021 | Gilead Sciences Ireland UC | Health | HIV & hepatitis-C healthcare policy and access to lifesciences innovation in Ireland (Matters involving public funds) | 4 | On lobbying.ie |
| Sep–Dec 2019 | Gilead Sciences Ireland UC | Health | Ireland's goal to eliminate Hepatitis-C by 2026 (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2019 | Gilead Sciences Ireland UC | Health | Ireland's goal to eliminate Hepatitis-C by 2026 (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2018 | Gilead Sciences Ireland UC | Health | Hepatitis C and HIV Healthcare (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2018 | Gilead Sciences Ireland UC | Health | HIV & Hepatitis C Healthcare Policy in Ireland (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2018 | Gilead Sciences Ireland UC | Health | HIV & Hepatitis C Healthcare Policy in Ireland (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2018 | Gilead Sciences Ireland UC | Health | HIV & Hepatitis C Health Policy in Ireland (Matters involving public funds) | 1 | On lobbying.ie |
| Sep–Dec 2017 | Gilead Sciences Ireland UC | Health | HIV & Hepatitis C health policy in Ireland (Matters involving public funds) | 6 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 27 | 100.0% |